Skip to main content

Table 5 Baseline characteristics according to allergy status

From: Real-life experience with benralizumab during 6 months

Variables Non-atopic
(n = 28)
Atopic
(n = 14)
p
Age, years; md (IR) 56 (20) 49.5 (15) 0.153
Women, n (%) 23 (82) 10 (71) 0.451
BMI, md (IR) 28.5 (7.5) 25 (10) 0.131
Age at diagnosis, years; md (IR) 26.5 (23) 24.5 (16) 0.913
Corticosteroid-dependent, n (%) 13 (46) 4 (28) 0.331
Nasal polyps, n (%) 5 (18) 7 (50) 0.067
AERD, n (%) 3 (11) 3 (21) 0.383
ACT, md (IR) 13 (6) 15 (6) 0.730
ED visits in the previous year; md (IR) 5 (3) 3 (3) 0.062
Cycles of OCS in the previous year; md (IR) 7 (3) 4.5 (4) 0.062
Oral prednisone (or equivalent) dose, mg/day; md (IR) 20 (15) 15 (23) 0.412
Post-BD FEV1, mL; md (IR) 1520 (910) 1425 (545) 0.947
Post-BD FEV1, %; md (IR) 65 (13) 69.5 (12) 0.117
FeNO, ppb; md (IR) 68.5 (32.5) 44.5 (45) 0.098
Blood eosinophil count, cells/μL; md (IR) 713 (297) 695 (235) 0.743
IgE, IU/mL; md (IR) 53 (106) 215 (175) < 0.001
  1. Abbreviations: ACT Asthma Control Test, AERD Aspirin-exacerbated respiratory disease, BD Bronchodilator, BMI Body mass index, ED Emergency department, FeNO Fractional exhaled nitric oxide, FEV1 Forced expiratory volume in 1 s, IR Interquartile range, md Median, ppb Parts per billion, OCS Oral corticosteroids